Last reviewed · How we verify

NCT06249581

Pharmacokinetics of AUX-001 40mg Once-daily in Healthy Subjects Under Fasting and Fed Conditions

Status unknown EARLY_PHASE1 Last updated 12 February 2024
What this trial tests

EARLY_PHASE1 trial testing AUX-001 40mg once-daily in Chronic Stable Angina in 16 participants. Status unknown.

Timeline
27 November 2023
Primary endpoint
8 February 2024
10 February 2024

Quick facts

Lead sponsorAuxilius Pharma sp.z.o.o.
PhaseEARLY_PHASE1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment16
Start date27 November 2023
Primary completion8 February 2024
Estimated completion10 February 2024
Sites1 location across Portugal

Drugs / interventions tested

Conditions studied

Sponsor

Auxilius Pharma sp.z.o.o. — full company profile →

Who can join

Adults 18 to 55, any sex, with Chronic Stable Angina. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Exploratory, single-dose, open-label, pharmacokinetic study to establish uptake, plasma levels safety and tolerability of orally administered AUX-001 on an empty stomach (i.e, fasting) as well as after a meal (i.e. fed) in healthy volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06249581.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing